Matina Stevis-Gridneff, a Brussels correspondent for The New York Times, dives into Europe's rocky vaccination journey. She reveals how the EU's cautious procurement strategies have led to serious delays, lagging behind countries like the U.S. and Israel. The discussion unpacks the public's diminishing trust in the AstraZeneca vaccine due to safety concerns and the EU's struggles with political pressure. Despite these challenges, Matina highlights the need for unity among member states and the potential ramifications on public health and tourism.
26:42
forum Ask episode
web_stories AI Snips
view_agenda Chapters
menu_book Books
auto_awesome Transcript
info_circle Episode notes
question_answer ANECDOTE
Early Pandemic Failures
During the initial COVID-19 outbreak, countries like Germany and France hoarded PPE.
This left Italy, severely impacted by the virus, without essential supplies.
insights INSIGHT
EU Vaccine Strategy
To prevent similar issues with vaccines, the EU centralized procurement.
They aimed to ensure fair distribution and better negotiating terms.
insights INSIGHT
Differing Approaches
The US invested heavily in vaccine development through Operation Warp Speed.
The EU acted more like a consumer, prioritizing cost-effectiveness.
Get the Snipd Podcast app to discover more snips from this episode
Long Bright River is a deeply affecting novel that delves into the lives of two sisters, Mickey and Kacey Fitzpatrick, in the Kensington neighborhood of Philadelphia. Mickey, a single mother and police officer, searches for her missing sister Kacey, who is struggling with addiction and works as a sex worker. The story unfolds as a mystery-thriller, with a series of murders involving prostitutes, forcing Mickey to confront their troubled childhood and the complexities of their relationship. The novel explores themes of addiction, family dynamics, and the broader social issues of poverty and community policing, offering a gripping and emotionally charged narrative[2][4][5].
Europe’s vaccination process was expected to be well-orchestrated and efficient. So far, it’s been neither. Sabrina Tavernise, a national correspondent for The Times, spoke with our colleague Matina Stevis-Gridneff about Europe’s problems and why things could get worse before they get better.
Guest: Matina Stevis-Gridneff, the Brussels correspondent for The New York Times, covering the European Union.
Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter.
Background reading:
A cascade of small decisions has led to increasingly long delays in the European Union’s inoculation efforts. While Washington went into business with the drug companies, Brussels took a conservative, budget-conscious approach that left the open market largely untouched. And it has paid for it.
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify.
The Daily 